A nine-gene molecular prognostic index provided accurate risk stratification and may be used to inform adjuvant therapy for patients with early-stage non–small cell lung cancer, according to the results of a retrospective analysis.“We set out to develop a predictor that could identify which patients with early-stage NSCLC are at highest risk for dying of the disease,” Maximilian

A nine-gene molecular prognostic index for patients with early-stage non-small cell lung cancer was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease, according to a study published Aug. 18 in the JNCI: Journal of the National Cancer Institute.

New advances have scientists banking on the idea that the most revealing medical test might be a single drop of your own blood

What is the most important thing that stakeholders should know about your research?

At the first annual Lung Cancer Early Detection and Prevention Workshop held at Cold Spring Harbor Laboratory (CSHL) in late September, nearly two dozen physicians, research scientists and hospital administrators took a close scientific view of rapid advances made in recent years to identify lung ca

The blood test can spot the traces of early lung cancer, long before it might be caught by an imaging test.

Using tumor samples from patients with non-small-cell lung cancer, the most common form of the disease, the scientists developed a test that accurately identified the earliest stage of the disease in half the people in the study and in all patients with more advanced lung cancer.

Early detection screening may be 5 to 10 years off, but the test may also be used for monitoring treatment much sooner

A new, highly sensitive blood test may help detect cancer tumors, Medical News Today reported.

New research suggests that soon doctors will be able to diagnose and track cancer through a simple blood test. Click to read more...

Maximilian Diehn, MD, PhD, an assistant professor in the Department of Radiation Oncology, Stanford Medicine, discusses some of the next steps researchers are taking with liquid biopsies in the field of lung cancer.

This peer-to-peer exchange highlights results of a study that tested whether analyzing circulating tumor DNA (ctDNA) during treatment with chemoradiotherapy could predict outcomes in patients with localized lung cancer.

The Pathway Genomics–created cancer test that was featured on 'Keeping Up With the Kardashians' is being investigated by CBS News for possibly promising patients more than current medical science can deliver — details

Pathway Genomics claims its liquid biopsy can detect cancer before patient shows symptoms - but expert says that promise is "years away"

Stanford researchers are able to find and analyze DNA that cancer cells shed into the bloodstream, offering them a way to monitor the progress of anticancer therapy,…